These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 28993873)

  • 1. Heart rate variability decreases after 3 months of sustained treatment with fingolimod.
    Vehoff J; Haegele-Link S; Humm A; Kaegi G; Mueller SK; Sauter R; Tettenborn BE; Hundsberger T
    J Neurol; 2017 Nov; 264(11):2313-2317. PubMed ID: 28993873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The autonomic balance predicts cardiac responses after the first dose of fingolimod.
    Rossi S; Rocchi C; Studer V; Motta C; Lauretti B; Germani G; Macchiarulo G; Marfia GA; Centonze D
    Mult Scler; 2015 Feb; 21(2):206-16. PubMed ID: 24957049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of fingolimod on cardiac autonomic regulation in patients with multiple sclerosis.
    Simula S; Laitinen T; Laitinen TM; Tarkiainen T; Hartikainen P; Hartikainen JE
    Mult Scler; 2016 Jul; 22(8):1080-5. PubMed ID: 26362903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis.
    Akbulak RÖ; Rosenkranz SC; Schaeffer BN; Pinnschmidt HO; Willems S; Heesen C; Hoffmann BA
    Mult Scler Relat Disord; 2018 Jan; 19():44-49. PubMed ID: 29127856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heart rate variability predicts the magnitude of heart rate decrease after fingolimod initiation.
    Simula S; Laitinen TP; Laitinen TM; Hartikainen P; Hartikainen JE
    Mult Scler Relat Disord; 2016 Nov; 10():86-89. PubMed ID: 27919506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central Autonomic Dysfunction Delays Recovery of Fingolimod Induced Heart Rate Slowing.
    Hilz MJ; Intravooth T; Moeller S; Wang R; Lee DH; Koehn J; Linker RA
    PLoS One; 2015; 10(7):e0132139. PubMed ID: 26147106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of sphingosine receptors influences circadian pattern of cardiac autonomic regulation.
    Simula S; Laitinen TP; Laitinen TM; Hartikainen P; Hartikainen JE
    Physiol Rep; 2016 Sep; 4(17):. PubMed ID: 27624686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequence of cardiovascular autonomic alterations after fingolimod initiation.
    Simula S; Laitinen TP; Laitinen TM; Hartikainen P; Hartikainen JEK
    Ann Noninvasive Electrocardiol; 2017 Sep; 22(5):. PubMed ID: 28191684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are there any clinical and electrocardiographic predictors of heart rate reduction in relapsing- remitting multiple sclerosis patients treated with fingolimod?
    Kocyigit D; Yalcin MU; Gurses KM; Tokgozoglu L; Karabudak R
    Mult Scler Relat Disord; 2019 Jan; 27():276-280. PubMed ID: 30447536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS).
    Meissner A; Limmroth V
    Mult Scler Relat Disord; 2016 Jul; 8():19-26. PubMed ID: 27456870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The management and outcomes of fingolimod first dose cardiac monitoring in UK patients with relapsing-remitting multiple sclerosis.
    Datt J; Baldock L; Pull E; Webber B
    Mult Scler Relat Disord; 2016 Jan; 5():40-6. PubMed ID: 26856942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice].
    Alcala-Vicente C; Perez-Miralles FC; Gascon-Gimenez F; Bosca-Blasco I; Navarre-Gimeno A; Coret-Ferrer F; Casanova-Estruch B
    Rev Neurol; 2017 May; 64(10):445-453. PubMed ID: 28497440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Three Months Fingolimod Therapy on Heart Rate.
    Simula S; Laitinen T; Laitinen TM; Tarkiainen T; Hartikainen JE; Hartikainen P
    J Neuroimmune Pharmacol; 2015 Dec; 10(4):651-4. PubMed ID: 26092537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod.
    Vanoli E; Montano N; De Angelis G; Badilini F; Mirabella M; Bonavita S; Patti F; Bianco A; Sparaco M; Chisari C; Laroni A; Frigerio F; Bartezaghi M; Rossi S; Turrini R; Mancardi G
    J Neurol Sci; 2019 Oct; 405():116423. PubMed ID: 31520869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic.
    Brown B; Weiss JL; Kolodny S; Meng X; Williams IM; Osborne JA
    BMC Neurol; 2019 Nov; 19(1):287. PubMed ID: 31729968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Safety and Patient Profile of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Prospective Analysis in Buenos Aires, Argentina.
    Rojas JI; Patrucco L; Miguez J; Cristiano E
    Clin Neuropharmacol; 2017; 40(6):251-254. PubMed ID: 28976408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
    Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
    Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
    Khatri B; Barkhof F; Comi G; Hartung HP; Kappos L; Montalban X; Pelletier J; Stites T; Wu S; Holdbrook F; Zhang-Auberson L; Francis G; Cohen JA;
    Lancet Neurol; 2011 Jun; 10(6):520-9. PubMed ID: 21571593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early safety and efficacy of fingolimod treatment in Denmark.
    Voldsgaard A; Koch-Henriksen N; Magyari M; Sellebjerg F; Sørensen PS; Oturai AB
    Acta Neurol Scand; 2017 Jan; 135(1):129-133. PubMed ID: 27910101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.